 1. To correlate established risk biomarkers such as cytomorphology obtained from random periareolar fine needle aspiration RPFNA, mammographic breast density, serum bioavailable estradiol and IGF-1IGFBP-3 with each other and with 5-10 year Gail risk estimates. Where available, and with appropriate safe guards to maintain status for breast cancer susceptibility genes may be included. 